╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Histologically or cytologically confirmed          │ Histologically or cytologically confirmed          │
│ adenocarcinoma of the breast with locally advanced │ adenocarcinoma of the breast with locally advanced │
│ or metastatic disease                              │ or metastatic disease, and a candidate for         │
│                                                    │ chemotherapy.                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Major surgical procedure or significant traumatic  │ Major surgical procedure or significant traumatic  │
│ injury within approximately 28 days prior to       │ injury within approximately 28 days prior to       │
│ randomization or anticipation of the need for      │ randomization or anticipation of the need for      │
│ major surgery during the course of study treatment │ major surgery during the course of study           │
│                                                    │ treatment.                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ a candidate for chemotherapy                       │ Histologically or cytologically confirmed          │
│                                                    │ adenocarcinoma of the breast with locally advanced │
│                                                    │ or metastatic disease, and a candidate for         │
│                                                    │ chemotherapy.                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ No prior chemotherapy for their metastatic breast  │ No prior chemotherapy for their metastatic breast  │
│ cancer (MBC)                                       │ cancer (MBC).                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of symptomatic congestive heart failure,   │ History of symptomatic congestive heart failure,   │
│ or ventricular arrhythmia requiring treatment      │ or ventricular arrhythmia requiring treatment.     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current severe, uncontrolled systemic disease (eg, │ Current severe, uncontrolled systemic disease (eg, │
│ clinically significant cardiovascular, pulmonary,  │ clinically significant cardiovascular, pulmonary,  │
│ or metabolic disease; wound healing disorders;     │ or metabolic disease; wound healing disorders;     │
│ ulcers; or bone fractures)                         │ ulcers; or bone fractures).                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Trastuzumab ≤ 21 days prior to randomization       │ Trastuzumab ≤ 21 days prior to randomization.      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current peripheral neuropathy of Grade ≥ 3         │ Current peripheral neuropathy of Grade ≥ 3.        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Age ≥ 18 years                                     │ Age ≥ 18 years.                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ An interval of < 6 months from the completion of   │ An interval of < 6 months from the completion of   │
│ cytotoxic chemotherapy in the neo-adjuvant or      │ cytotoxic chemotherapy in the neo-adjuvant or      │
│ adjuvant setting until the time of metastatic      │ adjuvant setting until the time of metastatic      │
│ diagnosis                                          │ diagnosis.                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of decreased LVEF or symptomatic           │ History of decreased LVEF or symptomatic           │
│ congestive heart failure (CHF) with previous       │ congestive heart failure (CHF) with previous       │
│ adjuvant trastuzumab treatment                     │ adjuvant trastuzumab treatment.                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current known infection with human                 │ Current known infection with human                 │
│ immunodeficiency virus (HIV), active hepatitis B   │ immunodeficiency virus (HIV), active hepatitis B   │
│ and/or hepatitis C virus                           │ and/or hepatitis C virus.                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Severe dyspnea at rest because of complications of │ Severe dyspnea at rest because of complications of │
│ advanced malignancy or requiring current           │ advanced malignancy or requiring current           │
│ continuous oxygen therapy                          │ continuous oxygen therapy.                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Contraception use must continue for the duration   │ For women of childbearing potential and men with   │
│ of study treatment and for at least 6 months after │ partners of childbearing potential, agreement to   │
│ the last dose of study treatment                   │ use a highly effective, non-hormonal form of       │
│                                                    │ contraception or 2 effective forms of non-hormonal │
│                                                    │ contraception by the patient and/or partner.       │
│                                                    │ Contraception use must continue for the duration   │
│                                                    │ of study treatment and for at least 6 months after │
│                                                    │ the last dose of study treatment. Male patients    │
│                                                    │ whose partners are pregnant should use condoms for │
│                                                    │ the duration of the study.                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known hypersensitivity to any of the study drugs,  │ Known hypersensitivity to any of the study drugs,  │
│ including the excipients, or any drugs formulated  │ including the excipients, or any drugs formulated  │
│ in polysorbate 80                                  │ in polysorbate 80.                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of exposure to the following cumulative    │ History of exposure to the following cumulative    │
│ doses of anthracyclines: Doxorubicin or liposomal  │ doses of anthracyclines: Doxorubicin or liposomal  │
│ doxorubicin > 500 mg/m^2; epirubicin > 900 mg/m^2; │ doxorubicin > 500 mg/m^2; epirubicin > 900 mg/m^2; │
│ mitoxantrone > 120mg/m^2 and idarubicin > 90       │ mitoxantrone > 120mg/m^2 and idarubicin > 90       │
│ mg/m^2                                             │ mg/m^2.                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hormone therapy < 7 days prior to randomization    │ Hormone therapy < 7 days prior to randomization.   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of any chemotherapy for MBC                │ History of any chemotherapy for MBC.               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current pregnancy or lactation                     │ Current pregnancy or lactation.                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Assessed by the investigator to be unable or       │ Assessed by the investigator to be unable or       │
│ unwilling to comply with the requirements of the   │ unwilling to comply with the requirements of the   │
│ protocol                                           │ protocol.                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Measurable disease                                 │ Measurable disease.                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Cardiac troponin I ≥ 0.2 ng/mL within 28 days of   │ Cardiac troponin I ≥ 0.2 ng/mL within 28 days of   │
│ randomization                                      │ randomization.                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current unstable angina                            │ Current unstable angina.                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Male patients whose partners are pregnant should   │ For women of childbearing potential and men with   │
│ use condoms for the duration of the study          │ partners of childbearing potential, agreement to   │
│                                                    │ use a highly effective, non-hormonal form of       │
│                                                    │ contraception or 2 effective forms of non-hormonal │
│                                                    │ contraception by the patient and/or partner.       │
│                                                    │ Contraception use must continue for the duration   │
│                                                    │ of study treatment and for at least 6 months after │
│                                                    │ the last dose of study treatment. Male patients    │
│                                                    │ whose partners are pregnant should use condoms for │
│                                                    │ the duration of the study.                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of intolerance (including Grade 3-4        │ History of intolerance (including Grade 3-4        │
│ infusion reaction) or hypersensitivity to          │ infusion reaction) or hypersensitivity to          │
│ trastuzumab, murine proteins, or docetaxel         │ trastuzumab, murine proteins, or docetaxel.        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Human epidermal growth factor receptor 2           │ Human epidermal growth factor receptor 2           │
│ (HER2)-positive                                    │ (HER2)-positive.                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Brain metastases that are untreated, symptomatic,  │ Brain metastases that are untreated, symptomatic,  │
│ or require therapy to control symptoms or any      │ or require therapy to control symptoms or any      │
│ radiation, surgery, or other therapy to control    │ radiation, surgery, or other therapy to control    │
│ symptoms from brain metastases within 2 months     │ symptoms from brain metastases within 2 months     │
│ prior to randomization                             │ prior to randomization.                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Previous radiotherapy for the treatment of         │ Previous radiotherapy for the treatment of         │
│ unresectable, locally advanced or metastatic       │ unresectable, locally advanced or metastatic       │
│ breast cancer is not allowed if more than 25% of   │ breast cancer is not allowed if more than 25% of   │
│ marrow-bearing bone has been irradiated or the     │ marrow-bearing bone has been irradiated or the     │
│ last fraction of radiotherapy has been             │ last fraction of radiotherapy has been             │
│ administered within approximately 3 weeks prior to │ administered within approximately 3 weeks prior to │
│ randomization                                      │ randomization.                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Left ventricular ejection fraction (LVEF) below    │ Left ventricular ejection fraction (LVEF) below    │
│ 50% within approximately 28 days prior to          │ 50% within approximately 28 days prior to          │
│ randomization                                      │ randomization.                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ agreement to use a highly effective, non-hormonal  │ For women of childbearing potential and men with   │
│ form of contraception or 2 effective forms of non- │ partners of childbearing potential, agreement to   │
│ hormonal contraception by the patient and/or       │ use a highly effective, non-hormonal form of       │
│ partner                                            │ contraception or 2 effective forms of non-hormonal │
│                                                    │ contraception by the patient and/or partner.       │
│                                                    │ Contraception use must continue for the duration   │
│                                                    │ of study treatment and for at least 6 months after │
│                                                    │ the last dose of study treatment. Male patients    │
│                                                    │ whose partners are pregnant should use condoms for │
│                                                    │ the duration of the study.                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of other malignancy within the last 5      │ History of other malignancy within the last 5      │
│ years, except for appropriately treated carcinoma  │ years, except for appropriately treated carcinoma  │
│ in situ of the cervix, non-melanoma skin           │ in situ of the cervix, non-melanoma skin           │
│ carcinoma, Stage I uterine cancer, or other        │ carcinoma, Stage I uterine cancer, or other        │
│ cancers with a similar outcome as those previously │ cancers with a similar outcome as those previously │
│ mentioned                                          │ mentioned.                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of myocardial infarction within 6 months   │ History of myocardial infarction within 6 months   │
│ prior to randomization                             │ prior to randomization.                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of receiving any investigational treatment │ History of receiving any investigational treatment │
│ within approximately 28 days prior to              │ within approximately 28 days prior to              │
│ randomization                                      │ randomization.                                     │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛